Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

GVK Biosciences and CRELUX set up fragment-based drug discovery platform to deliver lead molecules
April 2009
SHARING OPTIONS:

MUNICHGVK Biosciences and CRELUX announced in March that they have set-up a fragment-based drug discovery platform to deliver viable lead molecules.
 
The platform will integrate CRELUX's structural biology technologies with GVK's computer-assisted drug design tools and other components of its drug discovery and development engine. CRELUX will leverage its capabilities in all aspects of multifaceted structural studies towards X-ray elucidation of fragment or lead target complexes, while GVK BIO will perform all discovery chemistry and biology work including in silico, in vitro and in vivo studies as well as activities necessary to ensure preclinical candidate nomination. Financial terms were not disclosed.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.